Co-Diagnostics (NASDAQ:CODX) Given New $2.00 Price Target at HC Wainwright

Co-Diagnostics (NASDAQ:CODXFree Report) had its price objective lowered by HC Wainwright from $2.50 to $2.00 in a research note published on Monday, Benzinga reports. The brokerage currently has a neutral rating on the stock. HC Wainwright also issued estimates for Co-Diagnostics’ Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($1.15) EPS.

Co-Diagnostics Trading Down 3.2 %

CODX opened at $1.08 on Monday. The firm has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.21. Co-Diagnostics has a twelve month low of $0.98 and a twelve month high of $1.89.

Co-Diagnostics (NASDAQ:CODXGet Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). Co-Diagnostics had a negative net margin of 582.36% and a negative return on equity of 42.35%. The business had revenue of $0.47 million for the quarter, compared to the consensus estimate of $3.10 million. During the same period in the previous year, the firm earned ($0.20) EPS. Equities research analysts anticipate that Co-Diagnostics will post -0.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently bought a new position in Co-Diagnostics stock. SMI Advisory Services LLC purchased a new stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODXFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 17,499 shares of the company’s stock, valued at approximately $25,000. SMI Advisory Services LLC owned 0.06% of Co-Diagnostics as of its most recent SEC filing. 14.99% of the stock is owned by hedge funds and other institutional investors.

Co-Diagnostics Company Profile

(Get Free Report)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.

See Also

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with's FREE daily email newsletter.